11 results about "Immunomodulatory peptide" patented technology

The invention provides an allosteric nanogel adjuvant as well as a preparation method and application thereof, and belongs to the technical field of vaccines. The allosteric nanogel adjuvant comprises a self-assembly motif, a responsive site and an immunomodulatory peptide fragment, and the self-assembly motif is composed of 2-5 amino acids; the allosteric nanogel adjuvant has a structure as shown in a formula I, and is named as NTP5 for short; the allosteric nanogel adjuvant is self-assembled into nanoparticles, the nanoparticles are allosteric into a nanofiber structure through responsive broken bonds, nanogel is further formed, and the key problems of a traditional vaccine in the aspects of antigen delivery and immune activation are effectively solved. The nanogel adjuvant can efficiently load various antigens to form a stable nano vaccine, activate an immune microenvironment and provide more means and thoughts for vaccine development.

The application relates to the field of biotechnology, and particularly discloses an immunoregulatory peptide as well as a preparation method and application thereof. Three new polypeptides with ideal immunoregulatory effects are found through specific enzymolysis and screening, and the polypeptides have the amino acid sequences shown in any one or more of SEQ ID No. 1-3. The application enriches the types of milk-derived bioactive peptides, and provides new raw materials for preparing immunoregulatory effect products.

The application discloses an immunoregulatory peptide BugaCATH and application thereof, and belongs to the field of biomedicine. Buga The CATH is a cyclic polypeptide with a pair of intramolecular disulfide bond composed of a sixth cysteine and a thirteenth cysteine, and has a molecular weight of 3156.67 Dalton and an isoelectric point of 8.76, wherein the amino acid sequence is shown as SEQ ID NO: 2. Buga The gene (GenBank accession: OQ870533) of the CATH precursor is composed of 663 nucleotide sequences, and the nucleotide sequence is shown as SEQ ID NO: 1; wherein the nucleotide at the positions of 322-448 is the immunoregulatory peptide Buga The encoding gene of the CATH. The immunoregulatory peptide Buga The application of the CATH in the preparation of a treatment drug for promoting skin wound repair.

This invention specifically relates to spirulina immunomodulatory peptides, their preparation methods, and applications, belonging to the field of protein bioactive peptide technology. This invention is the first to screen immunomodulatory peptides Ser-Pro-Ser-Trp-Tyr (SPSWY), Met-Phe-Asp-Ala-Phe (MFDAF), and Phe-Gly-Arg-Phe-Arg (FGRFR) from spirulina phycocyanin. The structure and immunomodulatory activity of peptides SPSWY, MFDAF, and FGRFR were clarified. Peptides SPSWY, MFDAF, and FGRFR can enhance macrophage cell viability and phagocytic capacity, and also increase the secretion of NO and cytokines by macrophages. Their immunomodulatory activity also exhibits good stability. Furthermore, peptides SPSWY, MFDAF, and FGRFR have the advantages of being safe, non-toxic, and having high biological activity.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

This invention relates to the field of biomedical technology, and particularly to a process for preparing chicken thymus immunomodulatory peptides using a compound enzymatic hydrolysis method, the chicken thymus immunomodulatory peptides, and their applications. The steps are as follows: First, the chicken thymus tissue is pretreated, including thawing, cutting, microwave-assisted treatment, and high-speed homogenization. Then, pepsin pre-hydrolysis is performed, the pH is adjusted, and pepsin is added to the reaction. Next, the hydrolysis is optimized by pH gradient conversion (pH 4.8-5.2→6.3-6.7→7.3-7.7), followed by trypsin secondary hydrolysis. Then, the peptides are purified using a gradient membrane separation system (10kDa, 1kDa, 500Da), and the 1kDa-500Da fraction is collected. Finally, the collected fraction is concentrated and freeze-dried to obtain the target peptide. This process combines enzymatic hydrolysis and membrane separation technology to effectively extract highly active immunomodulatory peptides. The yield of active peptides in this invention is increased by approximately 42%, and the purity is increased by approximately 28%.

The application discloses an immunomodulatory peptide Ha-CATH and application thereof, and belongs to the field of biomedicine. The immunomodulatory peptide Ha-CATH is a cyclic polypeptide with a pair of intramolecular disulfide bonds formed by the eighth cysteine residue and the thirteenth cysteine residue of a skin repair peptide gene of Chinese amphibian Pelophylax nigromaculatus, has a molecular weight of 2361.8 Dalton, an isoelectric point of 6.04, and an amino acid sequence shown in SEQ ID NO:1. A gene (GenBank accession: OQ992774) encoding the precursor of the immunomodulatory peptide Ha-CATH is composed of 714 nucleotides, has a nucleotide sequence shown in SEQ ID NO:2, and the nucleotide sequence of 445-504 is the encoding gene of the immunomodulatory peptide Ha-CATH. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug.

Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The application discloses frog meat protein source active peptides and application thereof in preparation of immunomodulators, and belongs to the technical field of active peptides. Two novel immunomodulatory peptides GIHETTYNS and IVRDIKEK are identified from the hydrolysate of Rana spinosa meat, which can significantly improve the proliferation activity of macrophage RAW264.7, accelerate the cell cycle, promote the production of NO and cytokines, and improve the level of active oxygen. The results of inflammation reaction experiments show that the active peptides can relieve inflammation. The results of molecular docking show that the active peptides are combined with the key region of TLR4 / MD-2 through hydrogen bond and hydrophobic interaction. In addition, bioinformatics analysis shows that the active peptides have good safety and stability. In summary, the active peptides are expected to become new raw materials of natural immunomodulators and anti-inflammatory agents, and promote the high-value utilization of Rana spinosa.

The application discloses a preparation method of lactoferrin immunomodulatory peptide and application thereof. The application provides recombinant escherichia coli which is escherichia coli capable of expressing fusion protein SUMO-LF(IMP); the fusion protein SUMO-LF(IMP) is fused by a SUMO tag and lactoferrin immunomodulatory peptide (SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3). The recombinant strain of the application can efficiently express target protein, the expressed immunomodulatory active fragment retains natural immunomodulatory activity, and the prokaryotic expression system has the advantages of low culture cost, short fermentation period, easy separation and purification of protein and the like, the constructed strain can produce immunomodulatory active fragments on a large scale, provides a core production strain for product development in the fields of immunomodulators, biological pharmaceuticals, functional food additives and the like, and has important industrial application value and market prospect.

The application discloses a frog meat protein source active peptide with immunoregulation and anti-inflammatory functions and application thereof, and belongs to the technical field of active peptides. A novel immunoregulation peptide IADRMQKE is identified from anophrynus spinosus meat hydrolysate, which can significantly improve the proliferation activity of macrophage RAW264.7, accelerate the cell cycle, promote the production of NO and cytokines, and improve the active oxygen level. The results of inflammation reaction experiments show that the active peptide can relieve inflammation reaction. The results of molecular docking show that the active peptide is combined with the key region of TLR4 / MD-2 through hydrogen bond and hydrophobic interaction. In addition, bioinformatics analysis shows that the active peptide has good safety and stability. In summary, the active peptide is expected to become a new raw material of natural immunoregulator and anti-inflammatory agent, and promote the high-value utilization of anophrynus spinosus.